Trial Profile
A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BCHILD trial
- 14 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Jul 2028.
- 14 Feb 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jul 2028.
- 13 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.